| P50 | author | Jean-Luc Harousseau | Q3167165 |
| | Kenneth C. Anderson | Q28421846 |
| | Catherine Payen | Q117252292 |
| | Herve Avet-Loiseau | Q61112732 |
| | Thierry Facon | Q85789960 |
| | Paul G. Richardson | Q87712102 |
| | Philippe Moreau | Q87734443 |
| | Nikhil V Munshi | Q89228014 |
| | Laurent Garderet | Q92116116 |
| | Valérie Lauwers-Cancès | Q108429110 |
| | Claire Mathiot | Q114340053 |
| | Karim Belhadj | Q114340069 |
| | Michelle E Maglio | Q117224744 |
| | Margaret Macro | Q117224781 |
| | Nathalie Meuleman | Q117224782 |
| | Bertrand Arnulf | Q35109974 |
| | Martine Escoffre-Barbe | Q40290358 |
| | Murielle Roussel | Q56380622 |
| | Michel Attal | Q57306384 |
| P2093 | author name string | Xavier Leleu | |
| | Cyrille Hulin | |
| | Denis Caillot | |
| | Edie A Weller | |
| | Andrea A Zeytoonjian | |
| | IFM 2009 Study | |
| | Jean P Fermand | |
| | Sandrine Rollet | |
| P2860 | cites work | Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial | Q28252396 |
| | Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma | Q28266655 |
| | Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial | Q30433139 |
| | Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 |
| | Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma | Q57903998 |
| | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | Q57904272 |
| | Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma | Q58415969 |
| | A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 |
| | A note on quantifying follow-up in studies of failure time | Q71721709 |
| | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group | Q85187993 |
| | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma | Q33389111 |
| | Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du | Q33416427 |
| | Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | Q33431778 |
| | High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 |
| | Lenalidomide after stem-cell transplantation for multiple myeloma | Q34273726 |
| | International uniform response criteria for multiple myeloma. | Q34549410 |
| | Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 |
| | Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 |
| | Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms | Q36643453 |
| | Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation | Q36969778 |
| | Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies | Q37863988 |
| | Current strategies for treatment of relapsed/refractory multiple myeloma | Q38182683 |
| | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial | Q40899348 |
| | Assessment of minimal residual disease in myeloma and the need for a consensus approach | Q41556524 |
| | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma | Q41700620 |
| | Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma | Q41756273 |
| | Autologous transplantation and maintenance therapy in multiple myeloma | Q41756278 |
| | Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p | Q42781523 |
| | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial | Q42861085 |
| | Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. | Q42914716 |
| | Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study | Q43048164 |
| | Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma | Q43071494 |
| | Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma | Q43726973 |
| | Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study | Q43821016 |
| | Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. | Q46006794 |
| | Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial | Q46985882 |
| | Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial | Q47635702 |
| | Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial | Q53127020 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dexamethasone | Q422252 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 1311-1320 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma | |
| P478 | volume | 376 | |